Epidemiology and biomarkers in transplant associated thrombotic microangiopathy
A Prospective Validation Cohort Study: The goals are to prospectively assess the incidence of TA-TMA in a large pediatric cohort and to test a dynamic risk prediction tool that incorporates validated clinical and laboratory biomarkers in immune, endothelial, and complement activation pathways.
Funding: NIH/NHLBI - K23HL159271, April 1, 2022 - March 31, 2027
Epidemiology, health disparity, and risk stratification for cancer associated thrombosis
The goal of this project is to study the epidemiology and prevention of cancer-associated thrombosis and to determine the patient and societal impact of a thromboprophylaxis program.
Funding: Cancer Prevention & Research Institute of Texas (CPRIT) RR190104, Aug. 31, 2019 - Aug. 30, 2024
Risk factors and burden of COVID-19 related thrombosis and bleeding complication:
The goals are to determine the incidence of thrombosis and bleeding and to assess benefit/harm of therapeutic anticoagulation among hospitalized patients with COVID-19 across different hospital systems. There was a specific focus on people with cancer and thrombosis.
Funding: CDC - 6NU38OT000280-03-02, Sept. 1, 2020 - Jul 31, 2022
Management of thrombosis and bleeding in hematopoietic cell transplant patients:
The goals are to assess the incidence of and risk factors for thrombosis and bleeding in people undergoing hematopoietic cell transplantation. A novel risk prediction model was derived and externally validated.
Rapid diagnosis of immune thrombotic thrombocytopenic purpura
The goals are to characterize patients with high pre-test probability for iTTP. Specifically, a risk prediction model was derived and externally validated for iTTP.
Comparative and cost effectiveness research in hematology
The gaosl are to better understand the societal implications of novel treatment approaches in anticoagulation through systematic review, meta-analysis, and cost effectiveness analysis.